

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

In- Vivo Bioequivalence study of Aspirin tablets 81mg (Kharazmi Pharmaceuticals, Iran) with brand drug (ASPIRIN® 81mg Buyer, Germany) in Iranian healthy volunteers.

Protocol summary

Study aim

In- Vivo Bioequivalence study of Aspirin tablets 81mg (Kharazmi Pharmaceuticals, Iran) with brand drug (ASPIRIN® 81mg Buyer, Germany) in Iranian healthy volunteers.

Design

Single dose, randomized, two sequences, two period crossover with a washout period.

Settings and conduct

This study will be conducted in two-way, cross-over and fasting, and on two sets of healthy volunteers. The study will be conducted in two periods of twenty-four hours. The interval between these two periods, which is called the wash-out time, is determined by the half-life of the drug plasma, which according to scientific sources should be at least 5 to 7 half-life of the drug in the case of the drug under study. The plan will take a week to clean up the drug, given the biological half-life of the drugs in the drug form. In the first round, candidates are divided into two groups, and the first group receives a test tablet and the second group receives a similar tablet. Blood samples will be taken by the volunteer by the technician immediately after taking the drug, and the preparation steps of the samples, including plasma separation and drug extraction, are performed to analyze the amount of drug on them.

Participants/Inclusion and exclusion criteria

24 participants will be selected from non-smoking, not pregnant people with no history of heart, kidney and liver disease or dis functions with both sex (male&female). The ages and BMIs of participant should be in the range of 18-60 and 18-25 respectively.

Intervention groups

Both groups received in cross-over design medication and testing at two different cross-sections and Therefore, the test results are independent of individual differences and it will only show the difference in the

formulation of the two drugs.

Main outcome variables

Maximum plasma concentration of the drug, time to reach the maximum plasma concentration, drug excretion half-life, drug excretion constant

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200105046010N10**

Registration date: **2020-10-14, 1399/07/23**

Registration timing: **registered_while_recruiting**

Last update: **2020-10-14, 1399/07/23**

Update count: **0**

Registration date

2020-10-14, 1399/07/23

Registrant information

Name

Javad Shokri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3661 4125

Email address

shokri.j@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-09-21, 1399/06/31

Expected recruitment end date

2021-04-20, 1400/01/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

In- Vivo Bioequivalence study of Aspirin tablets 81mg (Kharazmi Pharmaceuticals, Iran) with brand drug (ASPIRIN® 81mg Buyer, Germany) in Iranian healthy volunteers.

Public title

Aspirin tablets 81mg (ASPIRIN® 81mg) Kharazmi , In-Vivo Bioequivalence in Iranian healthy volunteers.

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

General health(liver, heart, kidney) Body mass index(18-28) Informed consent Age(18-60)

Exclusion criteria:

Smoking A history of cardiovascular disease A history of liver & kidney disease Pregnancy Alcohol & Drug addiction Hypersensitivity to the drug

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

Bioequivalence

Groups that have been masked

- Participant

Sample size

Target sample size: **24**

Randomization (investigator's opinion)

Randomized

Randomization description

Random allocation law is the simplest method of finite randomization. This method represents a large block for the entire sample size. This means that a balance in the number of people assigned to each group will be achieved at the end of the study. For this purpose, first determine a total sample size (24 people), then write the names of the people on paper, and after folding in aluminum foil, pour it into a glass, and then randomly remove the papers and open the first 12 people in group A and The rest are selected as group B.

Blinding (investigator's opinion)

Single blinded

Blinding description

It is necessary to apply the scientific method of blind testing in some fields, such as drug testing. Candidates are not aware of the test drug or brand name. In a one-blind study, information that could distort the test result is hidden from the candidates, but the person in charge of the test is aware of it. Aspirin and Aspirin® are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form

Placebo

Not used

Assignment

Crossover

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Tabriz University of Medical Sciences Ethics Committee

Street address

No.48, Ferdowsi street, Ferdowsi Sq.

City

Tabriz

Province

East Azarbaijan

Postal code

5167874434

Approval date

2020-08-10, 1399/05/20

Ethics committee reference number

IR.TBZMED.REC.1399.505

Health conditions studied**1****Description of health condition studied**

In this study the bioequivalence of test and brand of Aspirin will be evaluated.

ICD-10 code**ICD-10 code description****Primary outcomes****1****Description**

Drug analysis in plasma or whole blood

Timepoint

Sampling times in this study will be 0 , 1, 2 , 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 12, 24 hours.

Method of measurement

High Performance Liquid Chromatography (HPLC)- Mass - Mass Spectrometer detector (MS/MS)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Single dose aspirin tablets 81 mg
Kharazmi Pharmaceutical Company.

Category

Treatment - Drugs

2

Description

Intervention group: Single dose aspirin tablet 81 mg
(ASPIRINE 81mg Tab) Made by the company (BUYER,
Germany).

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Simin Baspar Teyf Gostar Company

Full name of responsible person

Javad Shokri

Street address

No.48, Ferdos Street

City

Tabriz

Province

East Azarbaijan

Postal code

5167874434

Phone

+98 41 3384 2724

Email

Shokri.j@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Peymn Tarrahomi

Street address

No. 115 Kharazmi Pharmacy Deadlock, Shahid
Gholamreza Jalal St., Esteghlal Town, Tehran

City

Tehran

Province

Tehran

Postal code

1389716512

Phone

+98 21 4454 5413

Email

info@kharazmipharm.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Tabriz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Other

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Javad Shokri

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical
Sciences.

City

Tabriz

Province

East Azarbaijan

Postal code

5166414766

Phone

+98 41 3334 8489

Email

Shokri.j@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Javad Shokri

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical
Sciences.

City

Tabriz

Province

East Azarbaijan

Postal code

5166414766

Phone

+98 41 3334 8489

Email

Shokri.j@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Javad Shokri

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences.

City

Tabriz

Province

East Azarbaijan

Postal code

5166414766

Phone

+98 41 3334 8489

Email

Shokri.j@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

These data are as secure between researcher and related industries.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Only protocol and methods of study are sharable.

When the data will become available and for how long

After finishing of the protocol (Probably 6 months receiving IRCT code)

To whom data/document is available

Pharmaceutical and medical sciences researchers.

Under which criteria data/document could be used

Projects information's for any publications is not allowed.

From where data/document is obtainable

Contact with E-mail of the main researcher.

What processes are involved for a request to access data/document

Personal and academic details and the aim of the request.

Comments